4 Result(s)

Article

Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib

G H J Mickisch, B Escudier, S Walzer, M Nuijten in British Journal of Cancer (2010)

Article

Erratum: Letter to the Editor: SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival

Correction to: British Journal of Cancer (2010) 102, 232–233. doi: 10.1038/sj.bjc.6605446 Upon publication of this Letter to the Editor, it was noted that the affiliation for Dr Mark Nuijten had been presented...

M Nuijten, G Mickisch in British Journal of Cancer (2010)

Article

SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival

M Nuijten, G Mickisch in British Journal of Cancer (2010)

Article

Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib

Bevacizumab plus interferon-α2a (IFN) prolongs progression-free survival to >10 months, which is comparable with sunitinib as first-line treatment of metastatic renal cell carcinoma (RCC). The two regimens have d...

G Mickisch, M Gore, B Escudier, G Procopio, S Walzer… in British Journal of Cancer (2010)